SCHEMBL16093794

SCHEMBL16093794

CCCn1c2ccccc2c2c(OC)cccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 2/20 0.48
▸ PKM P14618 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ TSHR P16473 4/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ GAA P10253 1/20 0.44
▸ ALPL P05186 1/20 0.44
▸ ALPG P10696 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ HASPIN Q8TF76 1/20 0.43
▸ DYRK2 Q92630 1/20 0.43
▸ MAPT P10636 2/20 0.43
▸ USP2 O75604 2/20 0.43
▸ CASP1 P29466 2/20 0.43
▸ CASP7 P55210 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30213423 0.88 KCNA3 (0.49) CNR2ALDH1A1GAANPSR1HPGD
SCHEMBL15465904 0.87 ALDH1A1 (0.51) PKMMEN1KMT2ATSHRALDH1A1
SCHEMBL31609311 0.86 HASPIN (0.43) MEN1KMT2ATSHRALDH1A1ALPL
SCHEMBL13418983 0.84 RAD52 (0.49) PKMMEN1KMT2AALDH1A1GAA
SCHEMBL31609238 0.80 ENPP1 (0.42) MEN1KMT2AHPGDHASPINDYRK2
SCHEMBL31609306 0.80 PSEN1 (0.46) CNR2MEN1KMT2AHPGDHASPIN
SCHEMBL16093823 0.79 HPGD (0.52) CNR2ALDH1A1NPSR1HPGDMAPT
SCHEMBL16093825 0.79 PGR (0.41) CNR2ALDH1A1NPSR1HPGDHASPIN
SCHEMBL15465966 0.78 GPR3 (0.54) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL153959 0.77 ALDH1A1 (0.62) CNR2TSHRALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160024083-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2016-01-28 — — US disclosed
US-20160024083-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2016-01-28 — — US disclosed
US-20160024083-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2016-01-28 — — US disclosed
WO-2014153043-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2014-09-25 — — WO disclosed
WO-2014153043-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024083-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS AR, KLK3, BRDT CNR2 204/4885PKM 1102/4885MEN1 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback